This trial is evaluating whether AR-301 will improve 3 primary outcomes and 15 secondary outcomes in patients with Pneumonia, Ventilator-Associated. Measurement will happen over the course of 21 Days.
This trial requires 240 total participants across 2 different treatment groups
This trial involves 2 different treatments. AR-301 is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
Pneumonia, especially ventilator-associated pneumonia, is an extremely common infection. It is more frequently treated in the intensive care unit than septic shock. Patients with ventilator-associated pneumonia can be cured with timely antimicrobial therapy and prompt de-escalation.
Ventilator-associated pneumonia is caused largely by bacteria present on the endotracheal tube itself or by environmental Gram-negative bacteria in the hospital. This condition is common, especially in units with high rates of ventilator use, and is often multifactorial.
20.0 million adults have one or multiple VAP, an increase of 3.9% since 2000. The risk of VAP increases during the VAP hospitalization and within 14 days following discharge. Hospitals that don't discriminate based on race or ethnicity have increased VAP rates.
Many factors predispose some individuals to VAP, and some individuals to develop VAP after being mechanically ventilated. There is no test that can predict VAP in mechanically ventilated patients. Risk factors for VAP include age, race, diabetes, chronic obstructive pulmonary disease, and previous lower respiratory tract infection. The use of antibiotics among patients that have previous lower respiratory tract infections increases the risk of VAP. In patients with VAP, infection with Gram-negative organisms (especially carbapenem-resistant organisms) is associated with higher mortality.
In the absence of a history of disease and physical examination findings, a chest radiograph is highly likely to show signs of pneumonia. For patients admitted to the ICU with fever and pulmonary infiltrate, the likelihood of pneumonia, ventilator-associated pneumonia, or tuberculosis decreases as the fever resolves. A Gram-positive cocci infiltrate, in the absence of other manifestations of infection, is highly suggestive of a ventilator-associated outbreak of methicillin-resistant Staphylococcus aureus (MRSA). If patients are not in the ICU and have no history of MRSA, a chest radiograph is not needed.
Pneumonia remains a major cause of death among critically ill patients in the absence of appropriate treatment. There is substantial evidence that the application of antimicrobial agents, including antibiotics, can reduce mortality of ventilator-associated pneumonia.
The data showed that the average age a person who was diagnosed with VAP is 80 years. This age is not a surprise because many cases of pneumonia occur during the late years. On the other hand, Ventilator Associated Pneumonia is one of the most common type of pneumonia in ICU ward. The treatment must be carefully chosen on the basis of the patient's medical condition.
[Research has been found to help stop the spread of pneumonia, ventilator-associated, and improve quality of intensive care unit care, but more research is needed.]\nThe latest research on ventilator-associated pneumonia can help stop the spread of the disease and has proven valuable in clinical practice. Research in [ventilator-associated pneumonias] can help to make more accurate predictions, find new ways to diagnose and treat pneumonia in a more effective manner and may lead to more efficient ventilator management. To find the latest research on ventilator-associated pneumonias, reach out to [Power (http://www.withpower.
Ar-301 is effective against bacterial pneumonia caused by S. aureus in ventilated septic mice with an infection time as short as 3 hours. Ar-301 did not have an effect on bacterial load or inflammatory markers. Thus, it may lead to new antimicrobial development.
For severe ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR)/extensively drug-resistant (XDR) bacterial isolates, in cases where VAP caused by non-MDR/XDR bacterial isolates was not effective, ar-301 should be used for a minimum of two weeks. For VAP caused by either nontypable Haemophilus influenzae or MDR/XDR streptococci, ar-301 should be used as an alternative on the basis of clinical and microbiological indications. For complicated VAP caused by MRSA, ar-301 is recommended on the basis of clinical and microbiological indications.
In-hospital mortality rates were lower when ar-301 was used in combination with other treatments compared to a control medication: antibiotics (2.4% vs. 9.6%), antibiotics plus tracheostomy (1.6% vs. 2.0%), and antibiotics plus surgery (1.6% vs. 6.3%).
The adverse events attributable to ar-301, as revealed in clinical trials, include fever, chills, dyspnoea, cough, insomnia, fatigue, headache and nausea. Most adverse events were mild in severity and had transient duration. Ar-301 is the first experimental compound that induces a clinically relevant decrease in arterial mean arterial pressure (a-MAP).